Genmab A/S (GNMSF)
OTCMKTS · Delayed Price · Currency is USD
285.00
+0.83 (0.29%)
Sep 15, 2025, 12:37 PM EDT
Genmab Revenue
Genmab had revenue of $925.00M in the quarter ending June 30, 2025, with 18.74% growth. This brings the company's revenue in the last twelve months to $3.65B, up 32.97% year-over-year. In the year 2024, Genmab had annual revenue of $2.99B with 22.32% growth.
Revenue (ttm)
3.65B
Revenue Growth
+32.97%
P/S Ratio
4.75
Revenue / Employee
1.38M
Employees
2,682
Market Cap
17.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.99B | 545.24M | 22.32% |
| Dec 31, 2023 | 2.44B | 358.99M | 17.23% |
| Dec 31, 2022 | 2.08B | 796.62M | 61.88% |
| Dec 31, 2021 | 1.29B | -374.23M | -22.52% |
| Dec 31, 2020 | 1.66B | 855.79M | 106.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 105.45M |
| Tian'an Technology Group | 2.12M |
| Glass House Brands | 221.55M |
| Northwest Biotherapeutics | 1.09M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| AMJ Global Technology | 39.00 |
Genmab News
- 4 days ago - Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff - Seeking Alpha
- 5 days ago - Genmab: A Matter Of Time - Seeking Alpha
- 7 days ago - Genmab A/S (GMAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 7 days ago - Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - GlobeNewsWire
- 7 days ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire
- 7 days ago - 10 stocks to consider if you want alternatives to the expensive S&P 500 - Market Watch
- 13 days ago - AbbVie updates mid-stage trial data for Genmab-partnered lymphoma drug in outpatient setting - Seeking Alpha
- 14 days ago - Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) - Business Wire